2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

Abstract

PreambleSince 1980, the American College of Cardiology (ACC) and American Heart Association (AHA) have translated scientific evidence into clinical practice guidelines with recommendations to improve cardiovascular health. These guidelines, based on systematic methods to evaluate and classify evidence, provide a cornerstone of quality cardiovascular care.In response to reports from the Institute of Medicine1,2 and a mandate to evaluate new knowledge and maintain relevance at the point of care, the ACC/AHA Task Force on Clinical Practice Guidelines (Task Force) modified its methodology.3–5 The relationships among guidelines, data standards, appropriate use criteria, and performance measures are addressed elsewhere.5Intended UsePractice guidelines provide recommendations applicable to patients with or at risk of developing cardiovascular disease. The focus is on medical practice in the United States, but guidelines developed in collaboration with other organizations may have a broader target. Although guidelines may be used to inform regulatory or payer decisions, the intent is to improve quality of care and align with patients' interests. Guidelines are intended to define practices meeting the needs of patients in most, but not all, circumstances, and should not replace clinical judgment. Guidelines are reviewed annually by the Task Force and are official policy of the ACC and AHA. Each guideline is considered current until it is updated, revised, or superseded by published addenda, statements of clarification, focused updates, or revised full-text guidelines. To ensure that guidelines remain current, new data are reviewed biannually to determine whether recommendations should be modified. In general, full revisions are posted in 5-year cycles.3–6ModernizationProcesses have evolved to support the evolution of guidelines as “living documents” that can be dynamically updated. This process delineates a recommendation to address a specific clinical question, followed by concise text (ideally <250 words) and hyperlinked to supportive evidence. This approach accommodates time constraints on busy clinicians and facilitates easier access to recommendations via electronic search engines and other evolving technology.Evidence ReviewWriting committee members review the literature; weigh the quality of evidence for or against particular tests, treatments, or procedures; and estimate expected health outcomes. In developing recommendations, the writing committee uses evidence-based methodologies that are based on all available data.3–7 Literature searches focus on randomized controlled trials (RCTs) but also include registries, nonrandomized comparative and descriptive studies, case series, cohort studies, systematic reviews, and expert opinion. Only selected references are cited.The Task Force recognizes the need for objective, independent Evidence Review Committees (ERCs) that include methodologists, epidemiologists, clinicians, and biostatisticians who systematically survey, abstract, and assess the evidence to address syste...

Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial

“…This finding emphasises the importance of optimising treatment in the general peripheral artery disease population. 4,25,26 Consistent benefits in the reduction of major adverse cardiovascular events and major adverse limb events occurred with combination of rivaroxaban 2·5 mg plus aspirin compared with aspirin alone but did not occur to the same extent with the rivaroxaban 5 mg twice a day regimen. These results are also consistent with the results of the overall trial, which have been reported separately.…”

“…4 In addition to smoking cessation and exercise, statins, angiotensin converting enzyme (ACE) inhibitors, and antiplatelet agents (aspirin or a P2Y12 inhibitor) are used to reduce vascular complications. [4][5][6] Anticoagulant therapies have not been shown to be superior to antiplatelet therapy in peripheral artery disease and have unacceptably high rates of major bleeding.…”

“…4 In addition to smoking cessation and exercise, statins, angiotensin converting enzyme (ACE) inhibitors, and antiplatelet agents (aspirin or a P2Y12 inhibitor) are used to reduce vascular complications. [4][5][6] Anticoagulant therapies have not been shown to be superior to antiplatelet therapy in peripheral artery disease and have unacceptably high rates of major bleeding. 7 Specifically, high intensity (international normalised ratio [INR] of 3-4·5) and moderate intensity warfarin (INR 2-3) used with aspirin does not reduce major adverse cardiovascular events but does increase the risk of life-threatening bleeding, including intracranial haemorrhage.…”

Pathophysiology of Intermittent Claudication in Peripheral Artery Disease

“…19 Medical therapy for cardiovascular risk prevention in PAD has been reviewed elsewhere and updated in the recent AHA/ACC lower extremity guidelines. 20, 21 As outlined in the Table, several therapies have proven efficacy to reduce cardiovascular risk in PAD and are recommended as guideline-directed therapy.…”

Exercise Oxymetry in the Diagnosis of a Clinically Challenging Bilateral Socket Intolerance and Follow-up of An Apparently Inefficient Revascularisation

“…In the present case, due to renal failure, we were reluctant to perform contrast agent injection as a primary tool of proximal ischemia [7]. The initial Ex-tcpO 2 helped confirm the vascular origin of the pain and argued for the injected imaging with revascularization of arterial lesions.…”